PDL Biopharma Overview
- Year Founded
-
1986

- Status
-
Private
- Employees
-
328

- Latest Deal Type
-
IPO
- Latest Deal Amount
-
$96.8M
PDL Biopharma General Information
Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia, and Other countries, of which prime revenue is generated from Asia and North America.
Contact Information
Website
www.pdl.comCorporate Office
- 932 Southwood Boulevard
- Incline Village, NV 89451
- United States
Corporate Office
- 932 Southwood Boulevard
- Incline Village, NV 89451
- United States
PDL Biopharma Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. IPO | 20-Mar-1997 | $96.8M | Completed | Generating Revenue | ||
1. Early Stage VC | Completed | Startup |
PDL Biopharma Comparisons
Industry
Financing
Details
PDL Biopharma Competitors (15)
One of PDL Biopharma’s 15 competitors is Coherus Biosciences, a Formerly VC-backed company based in Redwood City, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
Hikma Pharmaceuticals | Corporation | London, United Kingdom | ||||
Jubilant Pharmova | Corporation | Noida, India | ||||
Astellas Pharma | Corporation | Tokyo, Japan | ||||
OPKO Health | Corporation | Miami, FL |
PDL Biopharma Patents
PDL Biopharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20090175847-A1 | Humanized antibodies to ab (20-42) globulomer and uses thereof | Inactive | 30-May-2007 | ||
US-20110008883-A1 | Mammalian cell-based immunoglobulin display libraries | Active | 01-Nov-2006 | ||
US-7700739-B2 | Complementary determining regions (cdr); interleukins (il-12) | Active | 30-Jun-2005 | ||
US-20100047245-A1 | Complementary determining regions (cdr); interleukins (il-12) | Active | 30-Jun-2005 | ||
US-20100196315-A1 | Il-12/p40 binding proteins | Active | 30-Jun-2005 | C07K16/244 |
PDL Biopharma Signals
PDL Biopharma Investments & Acquisitions (7)
PDL Biopharma’s most recent deal was a PIPE with Evofem Biosciences for . The deal was made on 10-Jun-2019.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Evofem Biosciences | 10-Jun-2019 | PIPE | Pharmaceuticals | ||
Evofem Biosciences | 11-Apr-2019 | PIPE | Pharmaceuticals | ||
Noden Pharma | 06-Jul-2016 | Merger/Acquisition | Pharmaceuticals | ||
Axogen | 14-Nov-2014 | PIPE | Biotechnology | ||
Avinger | 22-Apr-2013 | Mezzanine | Other Devices and Supplies |
PDL Biopharma ESG
Risk Overview
Risk Rating
Updated November, 02, 2020
29.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,189
Rank
Percentile

Pharmaceuticals
Industry
of 901
Rank
Percentile

Biotechnology
Subindustry
of 403
Rank
Percentile

PDL Biopharma FAQs
-
When was PDL Biopharma founded?
PDL Biopharma was founded in 1986.
-
Where is PDL Biopharma headquartered?
PDL Biopharma is headquartered in Incline Village, NV.
-
What is the size of PDL Biopharma?
PDL Biopharma has 328 total employees.
-
What industry is PDL Biopharma in?
PDL Biopharma’s primary industry is Drug Discovery.
-
Is PDL Biopharma a private or public company?
PDL Biopharma is a Private company.
-
What is the current valuation of PDL Biopharma?
The current valuation of PDL Biopharma is
. -
What is PDL Biopharma’s current revenue?
The current revenue for PDL Biopharma is
. -
How much funding has PDL Biopharma raised over time?
PDL Biopharma has raised $96.8M.
-
Who are PDL Biopharma’s competitors?
Coherus Biosciences, Hikma Pharmaceuticals, Jubilant Pharmova, Astellas Pharma, and OPKO Health are some of the 15 competitors of PDL Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »